Cartalax

Bioregulators Research compound (not approved for human use)

Synthetic tripeptide bioregulator (Ala-Glu-Asp) · also known as AED, Ala-Glu-Asp

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Cartalax is a short bioregulator tied in the originating literature to cartilage, skin fibroblasts and kidney cell cultures. Evidence is preclinical and concentrated in one group; the vial figures here are community conventions.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Also sold in 40 mg vials.

Phase	Dose	Volume	U-100 units
Starting	2 mg	0.3 mL	30
Standard	4 mg	0.6 mL	60
Higher	5 mg	0.75 mL	75

Frequency: Once daily, subcutaneous (8-12 week courses, community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Proposed to enter cells and interact with DNA minor-groove sequences, shifting expression of aging markers (p16, p21, p53, SIRT-6) in cultured cells; this remains a hypothesis.

Researched for

Studied in cultured renal and fibroblast cells for effects on proliferation and aging markers.
Investigated in cell models for influence on neuronal differentiation.
Described in reviews as a regulator of cartilage and skin-fibroblast function.

Notes

Both a 20 mg vial (about 6.67 mg/mL at 3 mL) and a 40 mg vial (about 13.3 mg/mL at 3 mL) are listed in the reference; the daily amounts are the same, so the drawn volume halves in the larger vial.
Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.

Sources

Last reviewed 2026-10-06.

Ovagen

Synthetic tripeptide bioregulator (Glu-Asp-Leu)

Ovagen is a three-residue peptide (glutamate, aspartate, leucine) from the Khavinson bioregulator family, linked to liver and kidney cell research.

20 mg vial · Once daily, subcutaneous (up to 16 weeks with gradual escalation, community-reported)

Vesugen

Synthetic tripeptide bioregulator (Lys-Glu-Asp)

Vesugen is a three-residue peptide (lysine, glutamate, aspartate) from the Khavinson family, associated with blood vessels and the cardiovascular system.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)